Caisse DE Depot ET Placement DU Quebec decreased its position in shares of Iqvia Holdings Inc (NYSE:IQV) by 37.1% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 12,060 shares of the medical research company’s stock after selling 7,100 shares during the quarter. Caisse DE Depot ET Placement DU Quebec’s holdings in Iqvia were worth $1,204,000 as of its most recent filing with the Securities & Exchange Commission.
Several other large investors have also recently bought and sold shares of the company. BlackRock Inc. boosted its holdings in Iqvia by 5.7% in the second quarter. BlackRock Inc. now owns 10,170,048 shares of the medical research company’s stock worth $1,015,173,000 after purchasing an additional 546,878 shares during the last quarter. Farallon Capital Management LLC boosted its holdings in Iqvia by 6.6% in the first quarter. Farallon Capital Management LLC now owns 3,158,647 shares of the medical research company’s stock worth $309,895,000 after purchasing an additional 195,703 shares during the last quarter. Dimensional Fund Advisors LP boosted its holdings in Iqvia by 39.2% in the first quarter. Dimensional Fund Advisors LP now owns 1,214,074 shares of the medical research company’s stock worth $119,113,000 after purchasing an additional 341,692 shares during the last quarter. Bank of New York Mellon Corp boosted its holdings in Iqvia by 5.9% in the second quarter. Bank of New York Mellon Corp now owns 1,194,110 shares of the medical research company’s stock worth $119,196,000 after purchasing an additional 66,748 shares during the last quarter. Finally, First Trust Advisors LP purchased a new stake in Iqvia in the second quarter worth approximately $99,127,000. Hedge funds and other institutional investors own 91.98% of the company’s stock.
Several equities research analysts recently issued reports on the stock. ValuEngine cut shares of Iqvia from a “buy” rating to a “hold” rating in a report on Friday, June 22nd. Royal Bank of Canada restated a “buy” rating and issued a $129.00 target price on shares of Iqvia in a report on Wednesday, July 25th. Piper Jaffray Companies restated a “hold” rating and issued a $97.00 target price on shares of Iqvia in a report on Wednesday, July 25th. Stifel Nicolaus increased their price target on shares of Iqvia from $128.00 to $150.00 and gave the stock a “buy” rating in a research report on Wednesday, July 25th. Finally, Barclays reiterated an “overweight” rating and issued a $130.00 price target (up from $120.00) on shares of Iqvia in a research report on Wednesday, July 25th. Five equities research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $126.79.
In other news, insider Robert Parks sold 871 shares of the firm’s stock in a transaction on Thursday, August 2nd. The shares were sold at an average price of $124.34, for a total transaction of $108,300.14. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Ronald A. Rittenmeyer sold 7,680 shares of the firm’s stock in a transaction on Thursday, July 26th. The shares were sold at an average price of $122.41, for a total transaction of $940,108.80. The disclosure for this sale can be found here. Insiders have sold a total of 978,777 shares of company stock worth $121,566,089 over the last 90 days. Insiders own 6.00% of the company’s stock.
Shares of IQV stock opened at $126.59 on Monday. The firm has a market cap of $25.35 billion, a PE ratio of 29.03, a PEG ratio of 1.80 and a beta of 0.70. Iqvia Holdings Inc has a one year low of $91.57 and a one year high of $128.40. The company has a debt-to-equity ratio of 1.40, a quick ratio of 1.13 and a current ratio of 1.13.
Iqvia (NYSE:IQV) last announced its quarterly earnings data on Tuesday, July 24th. The medical research company reported $1.29 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.14 by $0.15. The firm had revenue of $2.57 billion for the quarter, compared to the consensus estimate of $2.50 billion. Iqvia had a net margin of 12.68% and a return on equity of 13.51%. Iqvia’s revenue was up 9.0% compared to the same quarter last year. equities analysts forecast that Iqvia Holdings Inc will post 5.13 EPS for the current fiscal year.
IQVIA Holdings Inc provides integrated information and technology-enabled healthcare services in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Commercial Solutions, Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offers a range of cloud-based applications and related implementation, real-world insights, and reference information services; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services.
Featured Article: Price to Earnings Ratio (PE), For Valuing Stocks
Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Iqvia Holdings Inc (NYSE:IQV).
Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.